Biologic Input Output Systems
Private Company
Total funding raised: $14.5M
Overview
BIOS is a private, pre-revenue neurotech startup pioneering a direct peripheral nerve interface to create intuitive brain-machine connections. Founded in 2018 and based in San Francisco, the company leverages implanted electrodes, advanced robotics, and AI/ML to decode and encode neural signals for prosthetic control and sensory feedback. While its primary pipeline program targets upper-limb prosthetics, the 'universal' platform has long-term potential to interface with a wide array of digital health and assistive technologies. The company appears to be in a late-development or early clinical testing stage, building upon decades of foundational academic and DARPA-funded research.
Technology Platform
Universal Neural Interface (UNI): A bidirectional, implanted peripheral nerve interface that uses electrodes, AI/ML, and robotics integration to enable motor control and sensory feedback for prosthetic limbs and potential future devices.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
BIOS competes in the advanced BCI/prosthetics space against companies like Synchron and Paradromics (focused on central BCIs), as well as established prosthetic firms (e.g., Össur, Ottobock) integrating neural interfaces. Its key differentiation is the direct peripheral nerve interface for bidirectional control, contrasting with cortical implants or surface EMG-based systems.